A new daily pill could be a more effective GLP-1 tablet for weight loss, according to a clinical trial that may pave the way for an improved non-injection alternative to Wegovy and Mounjaro.
The drug, called orforglipron and manufactured by Eli Lilly, is prescribed for type 2 diabetes and targets the same GLP-1 receptors as oral semaglutide. Like semaglutide, it lowers blood sugar levels, slows digestion and suppresses appetite. Unlike semaglutide tablets, it does not need to be taken on an empty stomach.
